Alberto Martinez is President and CEO at Mundipharma in Europe, with a 15 year + trajectory in the pharmaceutical industry. Having started his career as a Sales Representative with Janssen in Spain, he joined Mundipharma in 2003, where he has held numerous leadership positions both at country and regional level. Alberto´s expertise is to lead business transformations, which he has done in every role he has held, ultimately driving an in-depth corporate turnaround of the Mundipharma network through strategic prioritisation and diversification. His leadership across the various organisations has consistently resulted in positive financial results combined with Great Place to Work awards, showing that organisations can thrive through transformations while securing sustainable growth. His passion is in building and working with high performing teams in a learning environment, putting people and a common purpose at the centre of everything he does. He holds a Ph.D. from Granada University and an Executive MBA from IE Business School, Spain.
Chris brings an invaluable mixture of sales, business development, market access and commercialisation expertise to his recent appointment as the European Director of Strategy and Commercial Excellence at Mundipharma. In this newly created role he is responsible for ensuring commercial excellence across our proven commercial platforms in specialist-driven primary care and specialty care, including our market leading biosimilars business in Europe.
Having started his pharmaceutical career in sales at Smiths Medical, Chris quickly progressed through positions of increasing responsibly with Cardinal Health, before joining Mundipharma as a Senior Business Development Manager in 2009. Since that time, he has excelled in various roles across the European network of independent associated companies including primary care sales in the UK, market access in the Netherlands and Director of the UK primary care business unit.
He holds a degree in International Business from Loughborough University Business School in the UK.
From October 2019 Chris became Senior Vice President, Business & Strategy.
Benoit joined the Mundipharma network of independent associated companies in 2010, initially as Strategy Analyst in France. He has held various positions in the UK and France, including Director of Strategy and Marketing at Mundipharma France. Benoit became General Manager of Mundipharma Belgium and Luxembourg in 2015 and manager for France and BeLux in 2016. His responsibilities from 2018 have expanded to include Switzerland.
Prior to joining the Mundipharma network, Benoit worked for various consultancy firms. He studied in E.M. Lyon Business School (MSc in Management).
From October 2019, Benoit became Vice President, Commercial Excellence.
Marco joined the Mundipharma network of independent associated companies in 2018 further enhance our external partnerships and medicine pipeline. Prior to joining Mundipharma Marco was Head of Business Development and Licensing at Helsinn and previously served as Head of Licensing for late stage assets since January 2016. Marco has significant commercial, development and strategic leadership expertise from an 11-year career in the pharmaceutical industry, with a specific focus on cancer supportive care and oncology. In his tenure at Helsinn he oversaw more than 50 licensing deals covering more than 190 countries around the world across cancer supportive care and oncology.
Marco holds a degree in Biotechnologies and a specialisation in industrial biotechnologies completed by an executive made to measure Master course in Business Administration from the Bocconi School of Management
Birgit has a degree in Pharmaceutical Science and an MBA in Economics. With more than 20 years of experience in the Pharmaceutical Industry, Birgit has worked in a variety of senior leadership roles within Novartis (Sandoz), LTS and Ratiopharm. Most recently, she was responsible for Technical Operations, Product Development and Strategic Planning at Aenova before joining Mundipharma as Global Senior Vice President (ex-US) Technical Operations. What drives her the most is making a difference to our patients’ lives by ensuring our products continue to be affordable.
Philippe has amassed experience across a range of industry sectors. He was most recently with FTSE 100 global medical technology company Smith & Nephew plc, where he was Group CIO. Before that, Philippe was Group CIO at the specialist insurer Beazley Group plc. He began his career in the automotive sector, taking various positions in the Renault Group, including Regional CIO for South America, where he was based in Curitiba, Brazil. Philippe then moved to the UK to become Information Officer in charge of sales and marketing systems for General Motors Europe.
In his current role, Philippe is accountable for the IT services provided to the global network of independent associated companies.
He was educated in France and holds an engineering degree from École Centrale de Paris and a PhD in technology from Université Paris VI, France. Philippe is married with four children and is fluent in four languages.
Anna joined Mundipharma in 2016 as Head of HR for the Mundipharma Nordic independent associated companies. She has through her career held senior global, European and regional HR roles with a focus on business transformation. Her broad cross-cultural experience is from across industries (Qlik, Yves Rocher, SAS Hotels), giving Anna a deep understanding for how to inspire and lead teams in multiple countries through a transformational journey, including the transformation of the Mundipharma Nordic independent associated companies.
Anna has BA degree in Public Administration, and did her Executive MBA at Instituto de Empresa in Madrid, Spain.
Alasdair is a General Counsel with extensive experience in some of the world’s most successful life sciences companies and law firms. He trained and qualified at Linklaters. Alasdair joined Mundipharma from Thermo Fisher Scientific (the world’s largest life sciences tools and healthcare technologies company) where he served as VP, General Counsel, EMEA. In 2018, he was awarded European General Counsel of the Year by the Association of Corporate Counsel.
He is currently completing an Executive MBA (London Business School) and holds a BSc in Biological Sciences (Edinburgh University). Alasdair is a Certified Director (INSEAD, IDP-C) and holds a Diploma in Company Direction (Institute of Directors).
Alasdair is a Trustee / Non-Executive Director (and Audit and Risk Committee Chair) of the UK Dementia Research Institute, the UK’s single biggest dementia investment, currently with 500 staff, and growing rapidly.
Neil started his legal career in 2002 when he joined London-based firm Bristows, specializing in intellectual property law. He moved in 2007 to Chicago, USA, obtaining his Juris Doctor from Northwestern University while working at the IP specialist firm, Banner & Witcoff, where he subsequently became a partner. In 2012, Neil returned to the UK to join Powell Gilbert LLP, continuing to specialize in patent litigation and advisory work in both high-tech and life sciences fields.
Neil joined the Mundipharma network in May 2015 as Director of European IP Strategy, moving quickly to Chief International IP Counsel.
Prior to studying law, Neil was awarded a PhD in biotechnology in 2001 from Cambridge University, UK, and he also holds a degree in molecular biology and biochemistry from Durham University, UK.
Hywel has over 20 years’ experience in the pharmaceutical industry and first joined Napp Pharmaceuticals in 1999 as a salesperson. During his time at Napp, Hywel has undertaken various roles across the business including marketing, market access and sales management.
In 2014 Hywel moved within the network to serve as the General Manager of the independent associated company in the Netherlands, which became the fastest growing company in the Dutch pharmaceutical industry. Hywel returned to the UK in 2017 as Managing Director of Napp where he has continued to deliver success. He believes in delivering commercial excellence across the business and that it is Napp’s people, who achieve this, in every interaction.
Anders began his pharma career with Eli Lilly where he held various positions in Sales and Marketing. He joined the Mundipharma network in 2006 as Marketing Manager in Denmark. Shortly thereafter, he accepted the opportunity to work in marketing for the network in Cambridge, UK delivering the first Pan-European launch for the Mundipharma network of independent associated companies. Anders has held various General Manager roles for the network, accepting the role of General Manager, Germany in early 2018.
Anders believes in empowering people to make the right decisions for successful businesses.
Francois Bernard holds the position of General Manager of Central & Eastern Europe & Emerging Markets. He joined the Mundipharma network of independent associated companies in 2012 as Head of Market Access and Communication before becoming General Manager of the independent associated company in South Africa in 2016. Prior to joining the network, Francois held a number of roles at Pfizer, including European Brand Director and Global Market Access Director. A physician by training (MD), he began his career at the French Health Care Authority, in charge of public health programmes and drug reimbursement assessment.
From October 2019, Francois has the added responsibilities for France and Switzerland.
Javier started his career in the pharmaceutical industry in Janssen Spain, where he worked for over ten years. Roles included Sales, Product Manager, Medical Liaison Manager and Marketing Director. He joined the Mundipharma network in 2008 holding various different positions including, Business Unit Manager, Commercial Director and, since 2015 and 2018 respectively, his current position as General Manager of Spain and Portugal.
Javier believes that people are key to success and is invested in helping his team deliver great work. As a consequence of this, the independent associated company in Spain maintains its no.11 position in its category at the Great Place to Work.
Brian joined Mundipharma in 2015 as Director of Projects and held a number of R&D roles in Cambridge and in Tokyo from Executive Director of Projects to Executive Director of Innovation and new product development.
He brings 20 years of experience in the pharmaceutical industry at companies such as Schering Plough and MSD with a track record of new product development and approvals in oncology and infectious diseases. He has successfully led R&D organisations and teams in Europe and in Asia (Japan and Singapore) and is a big advocate of teamwork, his motto being “great things happen when we work collaboratively together!” Brian started his career in the academic sector, including research positions at the Institute Pasteur in Paris and the Imperial College in London, and immediately prior to joining Mundipharma, he also spent 5 years on the leadership team of the Cancer Research UK Centre for Drug Development as Head of Project & Portfolio Management.
Brian holds a PhD in molecular biology from Trinity College, Dublin
James Leighton-Scott is the Senior Vice President Medical for Mundipharma. James joined Napp Pharmaceuticals in 2006 as a Medical Adviser, and has since undertaken a range of leadership roles within Mundipharma’s R&D and medical organisations. These roles include transforming Mundipharma’s drug safety group into a strategic partner, building a value-focussed clinical department, and consolidating two R&D sites into a single company based in Cambridge.
A physician by training, James is passionate about developing individuals and transforming teams through authentic leadership and learning.
Press return to search